LPCN
Lipocine Inc.NASDAQHealthcare$1.94-5.37%ClosedMarket Cap: $10.6M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.73
P/S
5.34
EV/EBITDA
-0.52
DCF Value
$0.75
FCF Yield
-92.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-8.9%
Operating Margin
-524.7%
Net Margin
-487.1%
ROE
-59.3%
ROA
-56.6%
ROIC
-71.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.1M | 98.7% | $-2.5M | $-2.4M | $-0.42 | — |
| FY 2025 | $2.0M | -334.3% | $-10.4M | $-9.6M | $-1.69 | — |
| Q3 2025 | $114.6K | 100.0% | $-3.4M | $-3.2M | $-0.59 | — |
| Q2 2025 | $622.8K | -243.1% | $-2.4M | $-2.2M | $-0.41 | — |
| Q1 2025 | $93.9K | 100.0% | $-2.1M | $-1.9M | $-0.35 | — |
| Q4 2024 | $3.5M | 100.0% | $1.5M | $1.8M | $0.32 | — |
| FY 2024 | $11.2M | 100.0% | $-1.2M | $8.4K | $-0.00 | — |
| Q3 2024 | $0.00 | NaN% | $-2.6M | $-2.2M | $-0.41 | — |
| Q2 2024 | $89.6K | -1993.1% | $-3.3M | $-3.1M | $-0.57 | — |
| Q1 2024 | $7.6M | 100.0% | $3.2M | $3.5M | $0.66 | — |
| Q4 2023 | $216.2K | 100.0% | $-2.6M | $-2.3M | $-0.43 | — |
| FY 2023 | $-2.9M | 456.9% | $-17.9M | $-16.4M | $-3.14 | — |